Key result
Platelet glycoprotein IIb/IIIa inhibitors potently inhibit platelet aggregation and are approved for use in coronary angioplasty and acute coronary syndromes.
Platelet glycoprotein IIb/IIIa inhibitors play a central role in preventing platelet aggregation during PCI and in the treatment of ACS.
No takes yet. Share an insight, caveat, or question.
GPIIb/IIIa inhibition may limit embolization in PCI; leaves open optimal agents, dosing, and outcomes in ACS.
Christopher P. Cannon (2003) conducted a review in Acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). Platelet Glycoprotein IIb/IIIa Inhibitors (abciximab, tirofiban, eptifibatide) was evaluated. Platelet glycoprotein IIb/IIIa inhibitors potently inhibit platelet aggregation and are approved for use in coronary angioplasty and acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: